Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers

医学 吉西他滨 内科学 肿瘤科 无进展生存期 人口 临床终点 胃肠病学 胆囊癌 顺铂 癌症 化疗 临床试验 环境卫生
作者
Rachna T. Shroff,Milind Javle,Lianchun Xiao,Ahmed O. Kaseb,Gauri R. Varadhachary,Robert A. Wolff,Kanwal Raghav,Michiko Iwasaki,Peter Masci,Ramesh K. Ramanathan,Daniel H. Ahn,Tanios Bekaii‐Saab,Mitesh J. Borad
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:5 (6): 824-824 被引量:471
标识
DOI:10.1001/jamaoncol.2019.0270
摘要

IMPORTANCE: Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and overall survival of 8.0 and 11.7 months, respectively. New treatments offering improved survival outcomes are therefore needed. OBJECTIVE: To evaluate the association between progression-free survival and the addition of nanoparticle albumin-bound (nab)-paclitaxel to gemcitabine-cisplatin for the treatment of patients with advanced biliary tract cancer. DESIGN, SETTING, AND PARTICIPANTS: This open-label, single-arm, phase 2 clinical trial conducted at the University of Texas MD Anderson Cancer Center and the Mayo Clinic in Phoenix, Arizona, enrolled 62 patients with advanced biliary tract cancers between April 14, 2015, and April 24, 2017. INTERVENTIONS: Patients initially received gemcitabine, 1000 mg/m2, cisplatin, 25 mg/m2, and nab-paclitaxel, 125 mg/m2, on days 1 and 8 of 21-day cycles. Owing to hematologic adverse events among the first 32 patients enrolled, these starting doses were reduced to 800, 25, and 100 mg/m2, respectively, for the remaining 28 patients. MAIN OUTCOMES AND MEASURES: The primary trial end point was investigator-assessed progression-free survival in the intention-to-treat population. RESULTS: Of 60 patients who started treatment, the mean (SD) age was 58.4 (11.0) years, 38 (63%) had intrahepatic cholangiocarcinoma, 9 (15%) had extrahepatic cholangiocarcinoma, 13 (22%) had gallbladder cancer, 47 (78%) had metastatic disease, and 13 (22%) had locally advanced disease. Median follow-up was 12.2 (95% CI, 9.4-19.4) months, and median progression-free survival was 11.8 (95% CI, 6.0 to 15.6) months. The partial response rate was 45%, and the disease control rate was 84%. Median overall survival was 19.2 months (95% CI, 13.2 months to not estimable). Patients in the safety population (n = 57) received a median of 6 (interquartile range, 3-11) cycles of treatment; 26 patients (46%) remained on their starting dose throughout the trial. Grade 3 or higher adverse events occurred in 58% of patients, and 9 patients (16%) withdrew owing to adverse events. Neutropenia was the most common grade 3 or higher adverse event, occurring in 19 patients (33%) overall. Post hoc analyses showed that treatment efficacy was not significantly associated with starting dose, tumor type, or disease status and that tolerability was improved with reduced- vs high-dose treatment. CONCLUSIONS AND RELEVANCE: Treatment with nab-paclitaxel plus gemcitabine-cisplatin prolonged median progression-free survival and overall survival vs those reported for historical controls treated with gemcitabine-cisplatin alone. These findings will be tested in a phase 3 randomized clinical trial. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02392637.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Mark完成签到,获得积分10
1秒前
1秒前
2秒前
思源的应助被Janice采纳,获得50
3秒前
点点完成签到 ,获得积分10
3秒前
王浩圳关注了科研通微信公众号
3秒前
4秒前
4秒前
Gaara0504发布了新的文献求助10
5秒前
nicheng发布了新的文献求助10
7秒前
8秒前
千凡完成签到,获得积分10
9秒前
tomatoGG发布了新的文献求助10
11秒前
今后的应助被September采纳,获得10
11秒前
sxt完成签到,获得积分20
11秒前
邓金涛发布了新的文献求助10
12秒前
13秒前
66完成签到 ,获得积分10
13秒前
15秒前
向雪完成签到 ,获得积分10
16秒前
16秒前
付冬晴完成签到,获得积分10
17秒前
Free发布了新的文献求助10
19秒前
王浩圳发布了新的文献求助10
20秒前
gy发布了新的文献求助10
20秒前
英勇的太兰完成签到 ,获得积分10
20秒前
20秒前
斯文败类的应助被本微尘采纳,获得10
20秒前
20秒前
September发布了新的文献求助10
23秒前
23秒前
24秒前
24秒前
小马甲的应助被爱笑凤凰采纳,获得20
25秒前
25秒前
王涛发布了新的文献求助30
26秒前
26秒前
钰拉A梦发布了新的文献求助10
27秒前
28秒前
如意山晴完成签到 ,获得积分10
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178960
求助须知:如何正确求助?哪些是违规求助? 9569638
关于积分的说明 21805682
捐赠科研通 7774071
什么是DOI,文献DOI怎么找? 3432955
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478640